BTAL Performance — AGF U.S. Market Neutral Anti-Beta Fund
Data updated: 2026-09-10
BTAL returned −22.20% year to date and −35.40% over one year to Jun 2026. Annualised returns are −12.46% over 3 years and −5.51% over 5 years. The fund trailed its US Mid-Cap Blend category average: $100 invested three years ago grew to $67, against $150 for the category, and to $65 over one year, against $122. Volatility over the past three years was 17.18% a year. In the 12 months to Jun 2026 the fund took in a net $148.4M, and assets reached $282.86M.
BTAL Growth of $100
What $100 invested in AGF U.S. Market Neutral Anti-Beta Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Mid-Cap Blend category average over the same months.
| Period | BTAL | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $65 | $122 |
| 3 years (Jul 2023 – Jun 2026) | $67 | $150 |
| 5 years (Jul 2021 – Jun 2026) | $75 | $147 |
| Since data start (Jan 2020 – Jun 2026) | $57 | $195 |
BTAL Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | −22.20% |
| 1 year | −35.40% |
| 3 years (annualised) | −12.46% |
| 5 years (annualised) | −5.51% |
BTAL Annual Returns
Calendar-year total returns of AGF U.S. Market Neutral Anti-Beta Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | −22.20% |
| 2025 | −20.60% |
| 2024 | +12.99% |
| 2023 | −14.85% |
| 2022 | +20.90% |
| 2021 | −7.33% |
| 2020 | −13.76% |
BTAL Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −1.2% | −1.2% | −0.6% | −10.5% | −7.9% | −2.8% | — | — | — | — | — | — |
| 2025 | −1.8% | +6.7% | +6.9% | −2.8% | −4.8% | −7.8% | −7.5% | −0.5% | −3.0% | −7.1% | +1.2% | −1.1% |
| 2024 | +8.4% | −1.4% | −0.2% | +4.7% | +1.7% | +1.5% | −0.9% | +3.6% | −2.0% | +0.6% | −5.0% | +2.1% |
| 2023 | −6.7% | −0.4% | +3.2% | +3.1% | −5.7% | −5.2% | −5.1% | +5.6% | +5.3% | +6.8% | −4.9% | −10.2% |
| 2022 | +5.3% | −3.9% | +2.3% | +8.0% | +2.3% | +7.2% | −8.0% | −1.5% | +3.2% | +2.0% | −0.7% | +3.9% |
| 2021 | +1.4% | −10.9% | −0.6% | −1.2% | −1.9% | +1.6% | +1.5% | −0.1% | −0.2% | −2.1% | +2.0% | +3.8% |
| 2020 | +5.6% | +0.7% | +8.7% | −3.2% | +1.2% | −3.3% | +2.6% | −4.7% | −0.5% | −2.8% | −14.5% | −2.5% |
BTAL Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 17.18%
- 3-year Sharpe ratio: -0.99 (vs 4.5% risk-free rate)
- Best month: +8.36% (Jan 2024)
- Worst month: −10.47% (Apr 2026)
BTAL Fund Flows
Monthly money in and out of AGF U.S. Market Neutral Anti-Beta Fund, from SEC Form N-PORT.
- 12-month net flow: $148.4M
- 12-month gross sales (incl. reinvestments): $399.5M
- Sales ÷ redemptions: 1.59×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $21.0M | $5.7M | $15.3M |
| May 2026 | $3.1M | $24.1M | −$21.0M |
| Apr 2026 | $7.6M | $53.1M | −$45.5M |
| Mar 2026 | $47.7M | $22.2M | $25.4M |
| Feb 2026 | $59.8M | $0 | $59.8M |
| Jan 2026 | $36.1M | $1.4M | $34.7M |
| Dec 2025 | $30K | $54.9M | −$54.9M |
| Nov 2025 | $33.9M | $21.8M | $12.2M |
| Oct 2025 | $57.1M | $40.9M | $16.2M |
| Sep 2025 | $15.0M | $27.0M | −$12.0M |
| Aug 2025 | $77.0M | $0 | $77.0M |
| Jul 2025 | $41.2M | $0 | $41.2M |
BTAL Assets Under Management
Net assets of AGF U.S. Market Neutral Anti-Beta Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $282.86M |
| 2026-03-31 | $407.99M |
| 2025-12-31 | $297.55M |
| 2025-09-30 | $361.86M |
| 2025-06-30 | $296.22M |
| 2025-03-31 | $408.44M |
| 2024-12-31 | $346.94M |
| 2024-09-30 | $411.26M |
| 2024-06-30 | $249.58M |
| 2024-03-31 | $232.78M |
| 2023-12-31 | $226.83M |
| 2023-09-30 | $300.00M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.